Reduced circulating CD63+ extracellular vesicle levels associate with atherosclerosis in hypercholesterolaemic mice and humans

This research demonstrates an inverse relationship between circulating EVs and cholesterol, making EVs a potential marker for cardiovascular disease (CVD). HFD causes reduced cardiac function, but atherosclerotic development is slowly progressing in hypercholesterolaemic models and only observed with old animals. These results also bring further evidence for the benefit of using of PCSK9 inhibitors as therapeutic agents in CVD.

Authors

Institutions

Publication Details

Journal
Cardiovascular Diabetology
Published
2024-10-17
DOI
https://doi.org/10.1186/s12933-024-02459-w
Citations
10
Primary Topic
Atherosclerosis and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
2.40

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reduced circulating CD63+ extracellular vesicle levels associate with atherosclerosis in hypercholesterolaemic mice and humans

Krisztína Németh, Tamás G. Gergely, Barbara W. Sódar, Johannes Oesterreicher et al.
10 citations
Cardiovascular Diabetology
Atherosclerosis and Cardiovascular Diseases
2.40
article

Reduced circulating CD63+ extracellular vesicle levels associate with atherosclerosis in hypercholesterolaemic mice and humans

Krisztína Németh, Tamás G. Gergely, Barbara W. Sódar, Johannes Oesterreicher, Nabil V. Sayour, Péter Ferdinandy, Xabier Osteikoetxea, Wolfgang Holnthoner, Zoltán V. Varga, András I. Försönits, Zoltán Giricz, Edit I. Buzás, Brachyahu Meir Kestecher, Bernadett R. Bodnár, S. Ghosal
article en
10 citations

Abstract

This research demonstrates an inverse relationship between circulating EVs and cholesterol, making EVs a potential marker for cardiovascular disease (CVD). HFD causes reduced cardiac function, but atherosclerotic development is slowly progressing in hypercholesterolaemic models and only observed with old animals. These results also bring further evidence for the benefit of using of PCSK9 inhibitors as therapeutic agents in CVD.

Cardiovascular DiabetologyVol. 23(1)
Semmelweis University (HU), Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA (AT), Montavid Thermodynamic Research Group (HU), Institute of Genetics (HU), Austrian Cluster for Tissue Regeneration (AT)
European Commission, Hungarian Scientific Research Fund, Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Horizon 2020 Framework Programme, National Research, Development and Innovation Office
Openalex Percentile: Top 11%
Atherosclerosis and Cardiovascular Diseases
2.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.